Navigation Links
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Date:8/17/2009

monstrated at Week 52. These differences did not achieve statistical significance. Furthermore, a favorable trend on the IPSS, as compared to placebo, was seen in a sub-group of patients with large prostate glands (greater than 50 cm3) on entry to the study.

Tolerability of cetrorelix in study Z-033 was very good, as evidenced by the absence of major differences to placebo with regard to both clinical adverse events or changes in laboratory parameters. The most frequently reported adverse experiences included hot flushes, nasopharyngitis, injection site pain, and headache, which is what was seen in the safety study Z-041. In particular, the incidence of hot flushes was lower than was seen in study Z-041 (see below), and they were also reported by patients randomized to placebo.

Study Z-041

In the safety study Z-041, all patients received cetrorelix by intra-muscular (IM) injection at Weeks 0 and 2, and were followed up to Week 26. The primary endpoint was the incidence of possibly drug-related adverse events; efficacy parameters were evaluated as secondary endpoints. The study was conducted in 68 sites in the United States and Canada.

Cetrorelix was generally well tolerated. Adverse events were mostly mild and transient in intensity. Serious adverse events occurred in 12 patients, but none of these was assessed as possibly drug-related. The most frequently reported adverse experiences included hot flushes, nasopharyngitis, injections site pain, and headache. Hot flushes were reported by 49 patients and were mild and of short duration in the majority of patients. Only one patient experienced a severe episode. A questionnaire was used to assess the local tolerance of the IM injection and affirmed the acceptability of this route of administration.

Efficacy was assessed using the IPSS which showed an improvement from a mean score of 21.2 at baseline to 15.6 at Week 26. In 63% of the patients, the improvement was
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
3. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
6. AEterna Zentaris Receives US$10 Million from Institutional Investors
7. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
8. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
10. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
11. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... CROWN POINT, Ind. , July 10, ... recently expanded its use of capnography for ... a growing group of healthcare leaders in ... Capnography measures how effectively patients are breathing ... respiratory depression occurs. By measuring the amount ...
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
(Date:7/10/2014)... April 15, 2014 -- According to the International ... nuclear security comes from terrorists acquiring sufficient quantities ... construct a crude nuclear explosive device. The IAEA ... trafficking have involved gram-level quantities, which can be ... According to a new study appearing this week ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2
... Jan. 5 Pharmatech, Inc. announces the launch of ... in oncology,along with other key company developments that will ... Pharmatech will feature a name change,from Pharmatech, Inc. to ... site,and emerging roles and responsibilities of the executive leadership ...
... Mach One Corporation,(Pink Sheets: MNCN), a biological solutions ... benefit to the agricultural and consumer,market, announced today that ... December 30, 2008 related to a proposed transaction with ... "BioPharm") to,acquire all of the outstanding member interests of ...
... Penn Allegheny,Health System and The Western Pennsylvania Hospital announced ... Jones, MD, FACS,and Roger R. Barrette, MD, formerly of ... Drs. Jones and Barrette will direct the ... for the treatment of burn injuries. West Penn,is ...
Cached Biology Technology:Pharmatech 2.0: Introducing Pharmatech Oncology 2Mach One Corporation Enters Letter of Intent 2West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists 2West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists 3
(Date:7/10/2014)... cities in New Mexico, nearly every public golf course ... precious potable water supplies. Across the U.S. Southwest as ... receive treated effluent. Reusing the effluent increases the sustainability ... homeowners alike fertilize their lawns during the growing season. ... Mexico State University turfgrass expert has a new vision ...
(Date:7/10/2014)... 2014 Smart technology emphasis grows in ... improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... Apple Inc. (NASDAQ: AAPL ), Visa Inc. (NYSE: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on ... second series of 30 second spots on CNBC for its ...
(Date:7/10/2014)... -- According to the new market research ... Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile ... Finance), and Geography - Global Trends & Forecasts to ... Sensors Market is projected to cross $14.35 Billion by ... 2014 to 2020. Browse more than 78 ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... The Patagonian Hippidion horse genus and North American stilt-legged ... tree, according to a new article in the open ... Alan Cooper, and colleagues use ancient DNA to argue ... and that American stilt-legged horses were American endemics, not ...
... of Toronto have mapped the molecular details that show ... immortalizes cells and causes them to continuously grow, thereby ... virus (EBV) is one of the most common human ... certain b-cell cancers like Burkitt's lymphoma as well as ...
... there's a recent wiki article with more details . New ... rat? A Guinea pig? Try none of the above. , A ... rodent with stubby legs and a tail covered in dense hair. ... actually more like a guinea pig or chinchilla. But not quite. ...
Cached Biology News:Ancient DNA helps clarify the origins of two extinct New World horse species 2U of T researchers map role of Epstein-Barr virus in cancer 2Scientists discover odd-ball rodent 2
... The Experion system, 100-120 and 220-240 ... all the steps of gel-based electrophoresis, including ... system configuration is used for protein analysis ... required for RNA analysis). The system includes ...
... ProteinChip Arrays are preactivated with carbonyl diimidazole ... amine groups. The PS10 array contains the ... array, but with an updated hydrophobic barrier ... with 2 mm diameter spots spatially compatible ...
... Activator of Caspase/DIABLO Liquid. In 100 ... FREEZE/THAW CYCLES. Amino acid residues 56 - 239 ... ® sequence was expressed in and purified ... along with cytochrome c during apoptosis ...
...
Biology Products: